DHA OMNIBUS IV Unrestricted & SB

DHA OMNIBUS IV Unrestricted and SB

General Description

Defense Health Agency (DHA) OMNIBUS IV Military Medical Research and Development 

This Indefinite Delivery/Indefinite Quantity (ID/IQ) multiple award contract provides a broad range of health-related research and development and support services that are of interest to the United States Department of Defense (DoD) and the Military Healthcare System.

Scope of Work/Program Areas

Medical Simulation Technologies – Includes but is not limited to systems, processes, or methods supporting medical simulation to increase military medical personnel’s knowledge, skills, and abilities to deliver combat casualty care support to manage patient injury and illness and to conduct patient movement from point of injury through role of care four.

Infectious Diseases – Includes but is not limited to medical readiness, vaccines, biology, prophylaxis/treatment drugs, diagnostics/prognostics, vector control, medical C4ISR, global and emerging disease countermeasures, and OCONUS field surveys (such as in Peru, Egypt, Cambodia, Italy, Singapore, and Thailand).

Military Health, Performance, and Recovery – Includes but is not limited to injury prevention and reduction; psychological health and resilience; post-traumatic stress disorder; physiological health; physical and cognitive performance; human physiologic and cognitive factors associated with various military operations to include sea, aviation, space and other related environments; aviation safety; aeromedical standards; altitude effects; acceleration effects; fatigue assessments; environmental and occupational health; exposures and environmental health and protection; nutrition and dietary supplements; conducting epidemiological studies investigating the longitudinal health of service members and their families; and developing and evaluating appropriate health surveillance and intervention strategies.

Joint Battlefield Healthcare – Includes but is not limited to damage control resuscitation, traumatic neuro-trauma and brain injury, combat trauma therapies, health monitoring and diagnostic technology, in route care, forward surgical and intensive critical care, traumatic tissue injury, and combat dentistry.

Radiation Health Effects – Includes directed energy biomedical research, women in proximity to nuclear power plants, post-exposure mitigation of radiation injury, protection and prevention of injury from ionizing radiation, understanding the mechanism of radiation injury, development of novel bio-dosimetry tools, and biomedical technology for radiation countermeasures.

Clinical & Rehabilitative Medicine – Includes but is not limited to rehabilitation (including neuro-musculoskeletal and craniofacial health and restoration); regenerative medicine and transplants; hearing, vision, and balance restoration; and pain management.

Chemical and Biological Readiness – Includes but is not limited to medical chemical research such as pretreatments, therapeutics, diagnostics, and basic research; and medical biological research such as vaccines, therapeutics, diagnostics, and basic research.

Clinical Investigations, Graduate Health Science Education, and Military Health System Research – Programs that respond to the needs of the Military Health System (MHS) and the dynamic nature of the health sciences through a focus on emerging research and training priorities established by the DoD and contribute to the high professional standing and accreditation of Graduate Health Science Education (GHSE) programs by fostering the conduct of research by both trainees and faculty. This includes Military Health System Research, which encourages research that examines the cost, quality, variation, outcomes, and policy of care delivered within either the purchased or direct care systems which is designed to provide new knowledge about the structure, processes, and effects of health care at the Military treatment Facility (MTF), Market and Enterprise levels.

Genomics and Omics-based – Includes but is not limited to clinical discovery, science, development, technologies, applications, translation, infrastructure, and program and policy activities; digital biobank development and execution; sample collection; gene sequencing; secure data storage; clinical precision medicine; and integration of omics, clinical, exposure, and military-specific data. Future discoveries and developments may drive additional contract needs to build DoD genomics program and to secure genetic information for operational security, biodefense, genetic defense, vaccine development, critical pharmacological independence, precision therapeutics, first-use identification, and future pandemic and epidemic agent identification.

Emerging Science and Technology – Includes but is not limited to new scientific areas or technology (possibly currently developing) with strong potential for military medical application and are of interest to DoD and the MHS. This is a complement to Program Areas 1 through 9 and designed to maintain 3 contract scopes for new discoveries or emerging technologies which present major opportunities for 5–10-year targeted investment with potential for transformative impact within the MHS. Investment in emerging S&T will be rare and can occur only after rigorous examination of the new area, its potential impact within the MHS, and its priority within the military medical R&D program.

Credence Segment

Credence holds Market Segment 2 (Research and Development Support Services). Under this segment, the contractor provides support for research activities rather than direct management and performance of the actual research. This includes tasks such as administration, staff support, subject matter expertise consulting, non-inherently government function management and oversight support to R&D leadership; drafting congressional responses regarding medical research programs; program management support; scientific/technical strategic planning; portfolio management; or execution management at the level of headquarters.

Contract Number

Credence Unrestricted Contract: HT001122D0016
Credence Dynamo Solutions Small Business Contract: HT001122D0015

Period of Performance

Base Period: September 1, 2021 – August 31, 2026
Option Period 01: September 1, 2026 – August 31, 2031

UEI Number


Contact Information

For detailed information on how Credence can meet your needs using this contract, please contact: CredenceOmnibusIV@credence-llc.com